As J&J’s oral IL-23 takes on Sotyktu, one-year follow-up data show durability: #AAD24

John­son & John­son un­veiled long-term ex­ten­sion da­ta on Sat­ur­day for a pro­gram it hopes can com­pete with Bris­tol My­ers Squibb’s So­tyk­tu in plaque pso­ri­a­sis.

Re­sults from the Phase IIb study show the drug, known as JNJ-2113 and co-de­vel­oped with Pro­tag­o­nist Ther­a­peu­tics, is able to main­tain much of its skin-clear­ing ef­fects to one year. The da­ta build on a 16-week read­out re­leased in Ju­ly 2023, and ex­pand­ed in the New Eng­land Jour­nal of Med­i­cine last month, which showed that JNJ-2113 hit on all pri­ma­ry and sec­ondary end­points in five dos­ing reg­i­mens.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.